Stocks / VRTX
VRTX stock forecast
VERTEX PHARMACEUTICALS INC · Healthcare · Biotechnology
The model's rating
Outperform
VRTX is rated Outperform as of September 29, 2026: its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth.
Create a free account to compare any two stocks; the numeric score is part of Premium.
VRTX is not among the 20 largest holdings published for 2026 Q4. See the portfolio
VRTX against the S&P 500
| Period | VRTX | S&P 500 (SPY) |
|---|---|---|
| 1 month | -4.0% | -0.3% |
| 3 months | +5.0% | +2.5% |
| Year to date | +15.3% | +12.7% |
| 1 year | +33.5% | +15.7% |
Total return, dividends included.
Key numbers
| Price | $522.81 |
| Market cap | 132.51 Billion |
| P/E (trailing 12 months) | 30.2 |
| P/S (trailing 12 months) | 10.5 |
| P/B (latest quarter) | 6.0 |
| Gross margin | 86.0% |
| Net profit margin | 35.0% |
| Return on equity | 23.3% |
| Beta | 0.5 |
As of August 4, 2026.
VRTX and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS INC | 78.07 Billion | Greatly Outperform | VRTX vs REGN |
| MRNA | MODERNA INC | 76.88 Billion | Greatly Underperform | VRTX vs MRNA |
| INCY | INCYTE CORP | 24.6 Billion | Greatly Outperform | VRTX vs INCY |
| TECH | BIO-TECHNE CORP | 11.36 Billion | Greatly Underperform |
Questions
What does the Upfront Investment model say about VRTX?
The model rates VERTEX PHARMACEUTICALS INC (VRTX) "Outperform" as of September 29, 2026, which means its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the VRTX rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is VRTX in the Upfront Investment model portfolio?
VRTX is not among the 20 largest holdings published for 2026 Q4.
The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.